Feasibility, Acceptability, and Adherence with Short-Term HIV Preexposure Prophylaxis in Female Sexual Partners of Migrant Miners in Mozambique

Maria Lahuerta, PhD, MPH,* Allison Zerbe, MPH,* Rachel Baggaley, MD,† Joana Falcao, MPH,* Laurence Ahoua, MD, MPH,* Pietro DiMattei, MD, MPH,* Fernando Morales, MD,* Isaias Ramiro, MD,§ and Wafaa M. El-Sadr, MD, MPH*†

Background: Preexposure prophylaxis (PrEP) offers protection from HIV acquisition if taken as prescribed. We evaluated the feasibility, acceptability, and adherence with short-term PrEP among female sexual partners of migrant miners in Mozambique.

Methods: HIV-negative female sexual partners of migrant miners were offered daily tenofovir/emtricitabine (TDF/FTC) for 6 weeks concurrent with miners’ return home. Study visits occurred at baseline, week 4, 6, and 8. Dried blood spots (DBSs) were collected at week 4 and 6.

Results: Seventy-four women (median age: 42 years) were enrolled, 95% reported having 1 sexual partner and 80% reported never or rarely using condoms. At baseline, 41% had never tested for HIV; 65% were unaware of partners’ HIV status. Of all women, 72 (97%) initiated PrEP, 7 (9%) discontinued PrEP before week 6; only 1 due to adverse events. Missed doses in the last week were self-reported by 8% and 3% of women at week 4 and 6, respectively. Of 66 (89%) women with DBS at week 4, 79% had detectable tenofovir diphosphate (TFV-DP) and 44% had levels consistent with $\geq 4$ pills/wk ($\geq 700$ fmol/punch). Of 63 (88%) women with DBS at week 6, 76% had detectable TFV-DP and 42% had levels consistent with $\geq 4$ pills/wk.

Conclusions: In this first study assessing the use of short-term PrEP, a high percent of female partners of migrant workers initiated PrEP and had detectable DP levels during follow-up. Further efforts are needed to enhance adherence to ensure protection from HIV acquisition. Short-term PrEP offers promise for populations who are at high risk of HIV during specific periods of time.

INTRODUCTION

Oral preexposure prophylaxis (PrEP), if taken as prescribed, is effective in prevention of HIV acquisition. Consequently, in 2015, the World Health Organization (WHO) recommended the use of PrEP for prevention of HIV acquisition by people at substantial risk of HIV.

Several studies have demonstrated that Mozambican miners working in South Africa and separated from their partners, often engage in high risk sexual activity—placing both themselves as well as their partners at home at risk of HIV acquisition. Gaza Province in southern Mozambique has the highest HIV prevalence in the country at 25%. This province also serves as a source of migrant labor for mines and industries in South Africa with male migrants returning for a long break in December (around Christmas) and a shorter break in March/April (around Easter). Data suggest that this migration contributes substantially to the epidemic in southern Mozambique. In a recent survey conducted in Gaza Province, 35% of migrant miners stated that they had engaged in sex outside of their marriage in the last 12 months and overall 46% reported never using condoms.

Given the specific circumstances of this population and high risk of HIV acquisition, novel approaches to HIV prevention are urgently needed. Mathematical models suggest that provision of time-limited PrEP to partners of miners could substantially reduce the cost per infection averted. However, to date, no study has assessed the feasibility, acceptability, and adherence with short-term PrEP during periods of heightened risk of HIV exposure. We evaluated the feasibility, acceptability, and adherence with short-term daily oral PrEP among HIV-negative female partners of male miners in Gaza Province, Mozambique.

METHODS

Study Setting and Population

The study took place between March and April 2016 in Chibuto and Xai–Xai, 2 districts of Gaza Province, in...
Mozambique. Participant recruitment and follow-up were conducted at TEBA offices, a labor agency that employs men in Mozambique and deploys them to work in mines in South Africa. Women were included in the study if they were 18 years of age or older, a female partner of a miner employed by TEBA, had a negative HIV test result per national HIV testing algorithm, had a serum creatinine below the upper limit of normal and calculated creatinine clearance >60 mL/min and provided written informed consent. Women were excluded if they had an hepatic alanine aminotransferase more than 2 times the upper limit normal; had symptoms of acute HIV infection; were pregnant or breastfeeding; had a history of kidney or other chronic disease; or if the miner partner was not coming to visit during Easter break in March/April 2016.

**Study Procedures**

Female partners of miners were informed of the study and, if interested, were referred to the study team. At baseline, eligible women who provided written informed consent were interviewed for sociodemographics, risk behaviors, HIV knowledge and attitudes, HIV prevention knowledge, and attitudes including the use of PrEP. Participants were counseled regarding how to take PrEP, the importance of adherence for PrEP to be effective, HIV risk reduction, condom use, and family planning.

Participants were instructed to take 1 tablet of tenofovir/entecitabine (TDF/FTC 200 mg/300 mg) orally daily for the 2 weeks before partner’s return, throughout the 2 weeks that their partner was home, and for 2 weeks after the partner returned to mines (total of 6 weeks). Participants were given a 5-week supply of TDF/FTC at baseline and a 3-week supply at week 4. Women were asked to return to the study office if they experienced any side effects, social harms, or symptoms of acute HIV infection.

At week 4 and 6, participants completed a follow-up questionnaire on behaviors, adherence, social harms, and adverse events. Additional counseling regarding PrEP adherence, HIV risk reduction, condom use, and family planning was provided at follow-up visits. Participants were tested for HIV and alanine aminotransferase. Dried blood spots (DBS) were collected. Two weeks after PrEP cessation (week 8), participants were assessed for adverse events and any social harm.

**Adherence Measurements**

Adherence with PrEP was ascertained using 3 methods: self-report, pill count, and tenofovir diphosphate levels in DBS. Pill count adherence was determined by counting the number of pills returned at week 4 and 6 visits and comparing with the expected number to have been used. DBS samples were assessed in a 3-mm DBS punch for tenofovir diphosphate levels using a validated liquid chromatography/tandem mass spectrometry method. The dynamic range of the assay was 25–6000 fmol per sample for TFV-DP.

**Ethical Considerations**

The protocol was approved by the Mozambique National Bioethics committee and the Institutional Review Boards at the WHO and Columbia University Medical Center.

**RESULTS**

**Study Participants**

Between February and March 2016, 97 women were screened for study eligibility, with 23 excluded. Primary reasons for ineligibility were being HIV-positive (9) and miner partner not returning during the planned study period (2).

A total of 74 women were enrolled in the study, with a median age of 42 years [interquartile range:37–50], the majority had at least some primary education (87%), most worked in agriculture or at home (78%) and 92% were married or living together with a partner (Table 1). More than one-third (41%) had never previously tested for HIV, whereas

| TABLE 1. Characteristics of Study Participants at Baseline (N = 74) |
|---------------------------------------------------------------|
| **n** | **%** |
|------|------|
| **Age, yrs** | | |
| Median (IQR) | 42 (IQR 37–50) |
| ≤35 yrs | 14 | 19 |
| Between 36 and 49 yrs | 41 | 55 |
| ≥50 yrs | 19 | 26 |
| **Highest level of education** | | |
| Never attended school | 10 | 13 |
| Some primary/primary completed | 50 | 68 |
| Some secondary/secondary completed | 14 | 19 |
| **Occupation** | | |
| Agriculture (home use) | 58 | 78 |
| Other occupations | 13 | 18 |
| Not working (retired) | 3 | 4 |
| **Type of relationship** | | |
| Married/living together | 68 | 92 |
| Not married, not living together | 6 | 8 |
| **Time of last HIV test** | | |
| Never tested | 30 | 41 |
| <3 mo | 10 | 14 |
| 3–6 mo | 14 | 19 |
| >6 mo | 20 | 27 |
| **Partner’s HIV status** | | |
| Does not know | 48 | 65 |
| HIV positive | 6 | 8 |
| HIV-negative | 20 | 27 |
| **Number of sexual partners in last 6 mo** | | |
| 1 partner | 70 | 95 |
| More than 1 partner | 3 | 4 |
| Refused | 1 | 1 |
| **Use of condoms with main partner** | | |
| Never/Rarely | 59 | 80 |
| Sometimes/often/always | 15 | 20 |
| **Number of children they have given birth to** | | |
| Median (IQR) | 5 (IQR 3–6) |
| Currently trying to have a baby | | |
| Yes | 10 | 14 |
| No | 64 | 86 |

IQR, interquartile range.
33% had received an HIV test within the past 6 months. Regarding the partner’s HIV status, 8% knew their partner was HIV positive, 27% reported their partner was HIV negative, and 65% did not know. No participant was diagnosed with HIV during follow-up.

Sexual Behaviors
At baseline, the majority (95%) reported having 1 sexual partner and 80% reported never or rarely using condoms (Table 1). Women reported a median of 5 (interquartile range: 3–6) births; 14% were currently trying to have a baby and 20% were using some family planning method. At week 4, all reported having sex with their partner since last visit, with 89% never or rarely using condoms. There were no changes reported in condom use during follow-up. During follow-up, only 1 woman reported having other sexual partners besides the main miner partner.

Uptake and Duration of PrEP Use
Of the 74 participants enrolled in the study, 72 (97%) initiated PrEP. One woman did not initiate because of fear and pressure from her family, whereas the other was taking traditional medicine. Overall, 66 (89%) reported taking PrEP for 4 weeks, 64 (86%) reported taking PrEP for 6 weeks and completed the week 6 visit, and 64 (86%) completed the week 8 visit (2-weeks after discontinuation). Seven participants (9%) discontinued PrEP before week 6 with only 1 due to side effects. Other reasons for discontinuing PrEP included: lack of time to return to the study office, traveling with the partner, and fear of family finding out. One woman was lost to follow-up since she was traveling outside of the country.

Adverse Events
The most common adverse events reported at week 4 were headache, fatigue, or dizziness (44%) followed by digestive problems (32%). No severe adverse events were reported. The proportion reporting adverse events decreased at week 6 visit, with 7 (11%) reporting headache, fatigue or dizziness, and 3 (5%) reporting digestive problems. Only 1 woman indicated stopping PrEP due to adverse events.

Adherence With PrEP
Self-reported adherence for the previous day was 98% and 97% at week 4 and 6, respectively, whereas 92% and 97% of the women reported having missed 1 or more doses in the previous 7 days, respectively (Table 2). At week 4 visit, 15 women (23%) reported always taking PrEP, as instructed, this percent increased to 69% by week 6. Based on the pill count data, the majority (92% and 90% at week 4 and 6, respectively) used more than 90% of expected doses. However, 12% informed their partner about their study participation. No social harms were reported during the study. By the end of the study, 98% of the 64 women interviewed at week 8 were willing to continue taking pills everyday to protect themselves from HIV, and all indicated that they would recommend PrEP to a family member or friend.

Acceptability of PrEP
The main reason reported by the women for participation in the study was to protect themselves from getting HIV infection through their partner’s sexual behavior. The majority disclosed study participation to a family member or friend (83% and 88% at week 4 and 6, respectively). However, 12% and 14% informed their partner about their study participation. No social harms were reported during the study. By the end of the study, 98% of the 64 women interviewed at week 8 were willing to continue taking pills everyday to protect themselves from HIV, and all indicated that they would recommend PrEP to a family member or friend.

### Table 2. Self-Reported Adherence, Drug Levels in Plasma, and Side Effects at Week 4 and 6

|                       | Week 4 Follow-up |          | Week 6 Follow-up |          |
|-----------------------|------------------|----------|------------------|----------|
|                       | (n = 66)         | n   | %   | (n = 64)         | n   | %   |
| **Self-reported adherence with PrEP medication the previous day** |                 |          |                  |          |
| Yes                   | 65               | 78 | 98  | 62               | 78 | 97  |
| No                    | 1                | 1  | 2   | 2                | 3  | 3   |
| **Number of doses missed in the previous 7 d (self-reported)** |                 |          |                  |          |
| None                  | 61               | 94 | 92  | 62               | 93 | 97  |
| One or more           | 5                | 8  | 8   | 2                | 3  | 3   |
| **Frequency of taking PrEP medication in the way that they were supposed to since last visit** |                 |          |                  |          |
| Sometimes             | 4                | 6  | 6   | 2                | 3  | 3   |
| Almost always         | 47               | 71 | 70  | 18               | 28 | 28  |
| Always                | 15               | 23 | 22  | 15               | 24 | 24  |
| **Adherence measured through pill count (number of days with pill taken)** |                 |          |                  |          |
| 90%–100%              | 61               | 92 | 90  | 60               | 90 | 90  |
| 80%–89%               | 4                | 6  | 3   | 5                | 3  | 5   |
| <80%                  | 1                | 2  | 3   | 1                | 3  | 3   |
| **Tenofovir diphosphate drug levels in dried blood spots** |                 |          |                  |          |
| $\geq$700 (4 or more tablets per week) | 29 | 44 | 28 | 44 |
| 350–699 (2–3 tablets per week) | 15 | 23 | 15 | 24 |
| <349 (<2 tablets per week) | 8  | 12 | 5  | 8   |
| Undetectable         | 14               | 21 | 21  | 15               | 24 | 24  |
| **Side effects experienced since last visit** |                 |          |                  |          |
| Headache/Fatigue/Dizziness | 29 | 44 | 7  | 11  |
| Digestive problems   | 20               | 32 | 3   | 5                | 3  | 5   |
| Others               | 12               | 19 | 11  | 6                | 9  | 9   |

*Pill count adherence was defined as ((Number of pills received − Number of pills returned + Number of pills damaged)/Number of days passed since previous appointment) × 100.
†The numbers do not add up to the total for week 6 as there was 1 participant at week 6 who did not provide a DBS sample.

with less than 2 tablets per week (<349 fmol/punch), and 14 (21%) had undetectable drug level. Of the 63 (88%) women with DBS at week 6, 76% had detectable levels of TFV-DP, with similar concentration distribution as at week 4 visit.
DISCUSSION

In this first study evaluating the use of short-term PrEP, we found that such use by female partners of migrant workers in Mozambique was feasible and acceptable in this high HIV prevalence setting. Uptake of PrEP was high, a large proportion of women had detectable TDF-DP levels during follow-up and the majority completed the PrEP course for the 6 weeks with almost half having levels consistent with ingestion of 4 or more pills in the previous week. Although reporting of adverse events was common early during PrEP use, this ameliorated during continued use and was largely not associated with discontinuation of PrEP. The high acceptability and uptake are consistent with findings from our previous qualitative study in this population.16

Our study focused on a population at substantial risk of HIV given that their main partners are migrant miners and based on findings from previous studies of high proportions of sex outside of their marriage and low condom use among these miners.11 Despite the promising results of PrEP as an HIV prevention strategy, few studies have evaluated the use of open-label PrEP among women in sub-Saharan Africa beyond the initial placebo-controlled clinical trials.17–19 Previous placebo-controlled studies that offered PrEP to women found adherence ranged from 20% to 80%, and a meta-analyses indicated that higher adherence of drug is needed to protect women from HIV infection.19–22 In this study, the proportion of participants with drug detected in the blood at week 6 (76%) were higher than that found in 2 placebo-controlled randomized PrEP trials, FEM-PrEP (less than 40%) and VOICE studies (29%), among women and similar to those found in the open-label daily PrEP in the HPTN 067 (ADAPT) study (79%).20–22 The higher adherence observed in this study might be due to the short-term duration of follow-up. Despite the high self-reported adherence, 44% of participants had an evidence of ingestion of 4 or more pills in the previous week, thought to provide protective drug levels. Our results highlight the challenges of assessing and supporting adherence to daily PrEP and the need to enhance adherence counseling.23

In this study, very few women (14%) disclosed to their partners that they were taking PrEP, which could have impacted adherence given that partner awareness and support have been noted as key facilitators for adherence among women taking PrEP.24–27 Although women reported that it might not be advisable to take PrEP without a partner’s approval, they also believed it was necessary to do so to protect themselves from HIV infection.16 This highlights the importance of supporting women in disclosing PrEP use, if they so desire. It is equally important to support women who choose not to disclose to their partners, providing them with the support they need to adhere with PrEP and avoid HIV infection. It is encouraging that the majority disclosed study participation to friends or family members. Finally, another important finding from our study is the substantial percent (9.3%) of women found to be HIV positive at screening who were all referred for HIV treatment. This highlights that the availability of PrEP may contribute to an increase in HIV testing coverage among vulnerable populations.

Given the small sample size and recruitment strategy, the findings may not be representative of all female partners of miners in Mozambique. However, this study involved a novel method for the use of oral PrEP in a population at substantial risk of HIV infection that has hitherto not been prioritized. Additional implementation science research is needed to build on our encouraging findings, determine how this intervention can be best implemented, and evaluate different types of adherence support to optimize the promise of PrEP in this population.

ACKNOWLEDGMENTS

The authors thank the women who participated in this study. We are also grateful to Peter Anderson from the University of Colorado for his support in conduct of the drug level analyses. We appreciate the support of the Ministry of Health in Mozambique and all the staff at the TEBA sites in Gaza Province, Mozambique.

REFERENCES

1. Hanscom B, Janes HE, Guarino PD, et al. Brief report: preventing HIV-1 infection in women using oral preexposure prophylaxis: a meta-analysis of current evidence. J Acquir Immune Defic Syndr. 2016;73:606–608.
2. Fonner VA, Dalglish SL, Kennedy CE, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS (London, England). 2016;30:1973–1983.
3. WHO. Guideline on When to Start Antiretroviral Therapy and on Preexposure Prophylaxis for HIV. Geneva, Switzerland: WHO; 2015.
4. Lurie MN, Williams BG. Migration and health in Southern Africa: 100 years and still circulating. Health Psychol Behav Med. 2014;2:34–40.
5. Lurie MN, Williams BG, Zuma K, et al. The impact of migration on HIV-1 transmission in South Africa: a study of migrant and nonmigrant men and their partners. Sex Transm Dis. 2003;30:149–156.
6. Zuma K, Gouws E, Williams B, et al. Risk factors for HIV infection among women in Carletonville, South Africa: migration, demography and sexually transmitted diseases. Int J STD AIDS. 2003;14:814–817.
7. Mozambique Ministry of Health. Behavioral risks, and information about HIV and AIDS in Mozambique. In: National Survey of Prevalence. Maputo, Mozambique: Ministry of Health; 2010.
8. Mozambique National Institute of Statistics. Projected population 2012. 2010. Available at: www.ine.gov.mz. Accessed March 10, 2017.
9. Crush J, Raimundo I, Simelane H, et al. Migration-induced HIV and AIDS in Rural Mozambique and Swaziland. South Africa: African Books Collection; 2010.
10. Foret KF, Barreto AT, Noya PA, et al. Population movements and the spread of HIV/AIDS in Mozambique. J Health Hum Serv Adm. 2001;24:279–294.
11. Martins-Fonteyn E, Loquiha O, Wouters E, et al. HIV susceptibility among migrant miners in Chokwe: a case study. Int J Health Serv. 2016;46:712–733.
12. Cremin I, Morales F, Jewell BL, et al. Seasonal PrEP for partners of migrant miners in southern Mozambique: a highly focused PrEP intervention. J Int AIDS Soc. 2015;18(4 suppl 3):19946.
13. Bushman LR, Kiser JJ, Rower JE, et al. Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection. J Pharm Biomed Anal. 2011;56:390–401.
14. Castillo-Mancilla J, Seifert S, Campbell K, et al. Emtricitabine-Triphosphate in dried blood spots as a marker of recent dosing. Antimicrob Agents Chemother. 2016;60:6692–6697.
15. Zheng JH, Rower C, McAllister K, et al. Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots. J Pharm Biomed Anal. 2016;122:16–20.
16. Falcão J, Ahoua L, Zerbe A, et al. Willingness to use short-term oral pre-exposure prophylaxis (PrEP) by migrant miners and female partners of migrant miners in Mozambique. Cult Health Sex. 2017. doi: 10.1080/13691058.2017.1314624.
17. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. *N Engl J Med.* 2012;367:399–410.

18. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. *N Engl J Med.* 2012;367:423–434.

19. Haberer JE. Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice. *Curr Opin HIV AIDS.* 2016;11:10–17.

20. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. *N Engl J Med.* 2012;367:411–422.

21. Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. *N Engl J Med.* 2015;372:509–518.

22. Bekker LG, Hughes J, Amico R, et al. HPTN 067/ADAPT Cape Town: a comparison of daily and nondaily PrEP dosing in African women. Paper presented at: Conference on Retroviruses and Opportunistic Infections 2015; February 23–26, 2015; Seattle, Washington. Abstract 978LB.

23. Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. *Lancet Infect Dis.* 2014;14:820–829.

24. Corneli A, Perry B, Agot K, et al. Facilitators of adherence to the study pill in the FEM-PrEP clinical trial. *PLoS One.* 2015;10:e0125458.

25. Montgomery ET, van der Straten A, Chidanyika A, et al. The importance of male partner involvement for women’s acceptability and adherence to female-initiated HIV prevention methods in Zimbabwe. *AIDS Behav.* 2011;15:959–969.

26. Namey E, Agot K, Ahmed K, et al. When and why women might suspend PrEP use according to perceived seasons of risk: implications for PrEP-specific risk-reduction counselling. *Cult Health Sex.* 2016;18:1081–1091.

27. Ware NC, Wyatt MA, Haberer JE, et al. What’s love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. *J Acquir Immune Defic Syndr.* 2012;59:463–468.